Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer

Part of paid clinical trials in Chicago, Illinois.

Sponsor
University of Chicago
Study ID
NCT01599793
Phase
PHASE2
Status
Completed

Conditions

  • Bone Metastases
  • Castrate-resistant Prostate Cancer
  • Recurrent Prostate Cancer
  • Stage IV Prostate Cancer

Eligibility Criteria

Sex
MALE
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • cabozantinib — DRUG
    Given PO
  • laboratory biomarker analysis — OTHER
    Correlative studies
  • magnetic resonance imaging — PROCEDURE
    Undergo MRI

Study Details

This study is being done to help researchers understand more about prostate cancer that has spread to the bones by using the newest magnetic resonance imaging (MRI) techniques and to better understand the effect of an experimental drug called XL184 (or cabozantinib) on bone disease. The other purposes of the study are to better understand the effect of XL184 on prostate cancer progression, bone pain, and on any cancer cells that patients may have circulating within the blood (called circulating tumor cells)

Key Dates

Start date
May 31, 2012
Status verified
Mar 2020
Primary completion
Dec 31, 2017
Completion
Dec 31, 2018

Study Design

Enrollment
19 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Treatment (enzyme inhibitor therapy)
    Patients receive cabozantinib PO QD. Treatment continues in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Change in the Functional MRI Metrics Ktrans Between 2 Weeks and Baseline [ Time Frame: baseline, 2 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of ChicagoChicagoIllinois60637-1470-

Find similar trials in Chicago, IL

By research site
University of Chicago· Chicago, IL

Related Studies